Rift Valley Fever Virus Vaccination Development

To assist in the development of novel vaccines and comprehensive strategies for the prevention of Rift Valley Fever virus in both livestock and humans using recombinant proteins and 96-well ELISA or Luminex platforms to detect anti-NP, anti-NSs or anti-NSm antibodies.
Funding Partners:
  • Texas A&M University
Program Partners:
  • CDC's National Center for Emerging and Zoonotic Infectious Diseases
Program Location:
  • United States of America